Market Trends of Europe Blister Packaging Industry
This section covers the major market trends shaping the Europe Blister Packaging Market according to our research experts:
Pharmaceutical is Expected to Witness a Significant Growth
- The pharmaceutical sector poses a different set of demands for blister packaging solutions, concerning insulation from external surroundings, cost-effectiveness, high levels of protection, and the ease of handling and retaining the effectiveness of the medicine.These packs are uniquely suited to meet stringent regulations and are highly valued for protective properties, cost-effectiveness, adaptability, and the pharmaceutical and packaging industry's requirements.
- When medicines are blister packaged, adherence is improved because consumers can keep track of their medications and dosage. The unit dosage feature of blisters reduces the risk of incorrect dosing.
- The retail-level preparation of prescription drugs is troubling pharmaceutical technicians or pharmacists. The administration of medicines in the open atmosphere of the supermarket and drug store may negatively affect sensitive medicines when they are transferred from container to container. Blister packaging can guarantee the process of distribution directly to the customer.
- Protecting product integrity continues to be the primary goal of pharmaceutical packaging, but there is continued work on cost reduction in the packaging process in all areas of the packaging industry. For instance, The Polybar barrier films product families provided by Amcor cover a wide range of moisture barriers whilst also providing good crush resistance to ensure the best protection for pharmaceutical applications such as tablets and capsules. It uses materials such as Aclar, COC, PE, PVC, and PVdc, among others.
- Further, the outbreak of the COVID-19 has increased the market for blister packaging. In October 2019, the Ukrainian pharmaceutical company Darnitsa passed the state registration for an experimental drug in the treatment protocol for COVID-19.
- A few countries across the region have banned the export of medicines that have shown efficacy in the fight against coronavirus infection, and first and foremost, meet the domestic demand. The Darnitsa pharmaceutical company passed the state registration for hydroxychloroquine substance - an experimental drug that is included in the treatment protocol for COVID-19.
Understand The Key Trends Shaping This Market
Download PDF
CIS Countries are Expected to WItness SIgnificant Growth
- Among the CIS countries, Russia is anticipated to hold a significant share. The pharmaceutical industry in Russia, one of the Commonwealth of Independent States (CIS) countries, can be considered one of the most complex sectors when considering the management of the intellectual property (IP), as it involves complicated legal, regulatory, linguistic, and marketing factors.
- The country has been witnessing significant growth in drug production. According to the Russian Ministry of Industry and Trade, the Russian government expects a 20% growth of domestic drug production in 2020, which is responsible for developing the pharmaceutical industry in the Russian government.
- According to the Minister, the expected growth will be comparable to that which was observed in the first four months of 2020 and was mainly due to the commissioning of some new production facilities within the country.
- However, the Russian government has also prepared a new strategy - the state program Pharma 2030, which should get the pharmaceutical sector's positive trends. The past decade's results, the expectations for the new program, and the promising areas and locations for investments in pharmaceuticals are mentioned in the Moscow Region Development Corporation (MRDC) material.
- And according to MRDC, in the near future, Russia will start implementing the state strategy of pharmaceutical industry development Pharma 2030. The strategy indicates the main industry directions, the growth of which will be stimulated with the help of the state support mechanisms.
- The state program of the country Pharma 2020 gave a strong impetus for developing the medical and pharmaceutical sectors, particularly at the initial stage of implementation. Industry players can expect a good start from the new state program, which is anticipated to augment the market growth in the CIS region.
Get Analysis on Important Geographic Markets
Download PDF
